Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141


Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia.

Santisteban M, Reynolds C, Barr Fritcher EG, Frost MH, Vierkant RA, Anderson SS, Degnim AC, Visscher DW, Pankratz VS, Hartmann LC.

Breast Cancer Res Treat. 2010 Jun;121(2):431-7. doi: 10.1007/s10549-009-0534-7.


p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia.

Radisky DC, Santisteban M, Berman HK, Gauthier ML, Frost MH, Reynolds CA, Vierkant RA, Pankratz VS, Visscher DW, Tlsty TD, Hartmann LC.

Cancer Prev Res (Phila). 2011 Dec;4(12):1953-60. doi: 10.1158/1940-6207.CAPR-11-0282.


Flat epithelial atypia and risk of breast cancer: A Mayo cohort study.

Said SM, Visscher DW, Nassar A, Frank RD, Vierkant RA, Frost MH, Ghosh K, Radisky DC, Hartmann LC, Degnim AC.

Cancer. 2015 May 15;121(10):1548-55. doi: 10.1002/cncr.29243.


Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer.

Visscher DW, Pankratz VS, Santisteban M, Reynolds C, Ristimäki A, Vierkant RA, Lingle WL, Frost MH, Hartmann LC.

J Natl Cancer Inst. 2008 Mar 19;100(6):421-7. doi: 10.1093/jnci/djn036.


Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.


Stratification of breast cancer risk in women with atypia: a Mayo cohort study.

Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, Maloney SD, Pankratz VS, de Groen PC, Lingle WL, Ghosh K, Penheiter L, Tlsty T, Melton LJ 3rd, Reynolds CA, Hartmann LC.

J Clin Oncol. 2007 Jul 1;25(19):2671-7.


Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer.

Barr FE, Degnim AC, Hartmann LC, Radisky DC, Boughey JC, Anderson SS, Vierkant RA, Frost MH, Visscher DW, Reynolds C.

Cancer Prev Res (Phila). 2011 Mar;4(3):435-44. doi: 10.1158/1940-6207.CAPR-10-0242.


ERβ expression and breast cancer risk prediction for women with atypias.

Hieken TJ, Carter JM, Hawse JR, Hoskin TL, Bois M, Frost M, Hartmann LC, Radisky DC, Visscher DW, Degnim AC.

Cancer Prev Res (Phila). 2015 Nov;8(11):1084-92. doi: 10.1158/1940-6207.CAPR-15-0198.


Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study.

Hartmann LC, Radisky DC, Frost MH, Santen RJ, Vierkant RA, Benetti LL, Tarabishy Y, Ghosh K, Visscher DW, Degnim AC.

Cancer Prev Res (Phila). 2014 Feb;7(2):211-7. doi: 10.1158/1940-6207.CAPR-13-0222.


Clinicopathologic features of breast cancers that develop in women with previous benign breast disease.

Visscher DW, Frost MH, Hartmann LC, Frank RD, Vierkant RA, McCullough AE, Winham SJ, Vachon CM, Ghosh K, Brandt KR, Farrell AM, Tarabishy Y, Hieken TJ, Haddad TC, Kraft RA, Radisky DC, Degnim AC.

Cancer. 2016 Feb 1;122(3):378-85. doi: 10.1002/cncr.29766.


Subgroups of non-atypical hyperplasia of breast defined by proliferation of oestrogen receptor-positive cells.

Iqbal M, Davies MP, Shoker BS, Jarvis C, Sibson DR, Sloane JP.

J Pathol. 2001 Mar;193(3):333-8.


Identification of a chemoprevention cohort from a population of women at high risk for breast cancer.

Fabian CJ, Kamel S, Zalles C, Kimler BF.

J Cell Biochem Suppl. 1996;25:112-22.


Immunodetectable cyclin D(1)is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions.

Shoker BS, Jarvis C, Davies MP, Iqbal M, Sibson DR, Sloane JP.

Br J Cancer. 2001 Apr 20;84(8):1064-9.


A framework for quantitative assessment of Ki67 distribution in preneoplastic bronchial epithelial lesions.

Khojasteh M, Buys TP, LeRiche J, Lam S, Guillaud M, MacAulay C.

Anal Quant Cytol Histol. 2012 Jun;34(3):120-38.


Scintimammographic detection of usual ductal breast hyperplasia with increased proliferation rate at risk for malignancy.

Papantoniou V, Tsiouris S, Koutsikos J, Sotiropoulou M, Mainta E, Lazaris D, Valsamaki P, Melissinou M, Zerva C, Antsaklis A.

Nucl Med Commun. 2006 Nov;27(11):911-7.


Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression.

Shaaban AM, Sloane JP, West CR, Foster CS.

Am J Pathol. 2002 Feb;160(2):597-604.


Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma.

Laurinavicius A, Plancoulaine B, Rasmusson A, Besusparis J, Augulis R, Meskauskas R, Herlin P, Laurinaviciene A, Abdelhadi Muftah AA, Miligy I, Aleskandarany M, Rakha EA, Green AR, Ellis IO.

Virchows Arch. 2016 Apr;468(4):493-502. doi: 10.1007/s00428-016-1907-z.


Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.

Gerring Z, Pearson JF, Morrin HR, Robinson BA, Harris GC, Walker LC.

Histopathology. 2015 Oct;67(4):538-47. doi: 10.1111/his.12678.

Items per page

Supplemental Content

Support Center